Extracorporeal Photopheresis — NCD 113 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 113 governing extracorporeal photopheresis coverage, with an effective date of March 7, 2026. Here's what billing teams need to know.

CMS extracorporeal photopheresis coverage policy under NCD 113 in the Medicare system covers three distinct indications — each with its own effective date and medical necessity criteria. This modification clarifies the clinical and research-based conditions under which extracorporeal photopheresis billing will be reimbursed. No specific CPT or HCPCS codes are listed in the policy document, which creates real chargemaster questions your billing team needs to resolve now.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	Extracorporeal Photopheresis
Policy Code	NCD 113
Change Type	Modified
Effective Date	2026-03-07
Impact Level	Medium-High
Specialties Affected	Hematology/Oncology, Transplant Medicine, Pulmonology, Dermatology
Key Action	Audit your ECP claims against all three indication tiers and confirm your MAC's billing requirements before March 7, 2026

---

CMS Extracorporeal Photopheresis Coverage Criteria and Medical Necessity Requirements 2026

NCD 113 is the National Coverage Determination governing Medicare coverage of extracorporeal photopheresis (ECP). The procedure removes a patient's blood, centrifuges it to isolate white blood cells, exposes those cells to 8-methoxypsoralen (8-MOP) and ultraviolet A (UVA) light, then re-infuses the treated cells. The 8-MOP can be administered ex vivo — directly to the isolated white blood cells — or administered to the patient before withdrawal.

CMS covers ECP under three separately authorized indications. Each one has its own effective date. Medical necessity documentation must align with the specific indication you're billing — not the procedure in general.

Indication 1: Cutaneous T-Cell Lymphoma (effective April 8, 1988)

Coverage applies to palliative treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL). The disease must not have responded to other therapy. This is the original covered indication and remains active under the updated coverage policy.

Indication 2: Cardiac Allograft Rejection and Chronic Graft Versus Host Disease (effective December 19, 2006)

CMS covers ECP for two populations under this tier:

#	Covered Indication Copy
1	Patients with acute cardiac allograft rejection whose disease is refractory to standard immunosuppressive drug treatment
2	Patients with chronic graft versus host disease (cGVHD) whose disease is refractory to standard immunosuppressive drug treatment

The word "refractory" is doing a lot of work here. Your documentation must show the patient failed standard immunosuppressive therapy before ECP is authorized. Missing that documentation is the fastest route to a claim denial.

Indication 3: Bronchiolitis Obliterans Syndrome (effective April 30, 2012)

This is the most restrictive tier. Coverage requires all of the following:

The clinical research study must meet specific CMS standards. These include a prospective design, written protocol, IRB compliance under 45 CFR Part 46, FDA compliance under 21 CFR parts 50 and 56 if applicable, and alignment with ICMJE scientific integrity standards. The study must address at least one of three patient-centered outcomes: improved FEV1, improved survival after transplant, or improved quality of life.

This coverage policy for BOS is not routine care authorization. It is coverage for research participation only. If your facility is billing ECP for BOS outside an approved clinical study, those claims are not covered under NCD 113.

Prior authorization requirements are not explicitly listed in this NCD. However, your Medicare Administrative Contractor (MAC) may have additional local coverage requirements. Check with your MAC before assuming NCD 113 alone clears the claim.

---

CMS Extracorporeal Photopheresis Exclusions and Non-Covered Indications

Any ECP indication not listed under the three covered tiers is non-covered under this NCD. CMS does not provide an exhaustive list of excluded diagnoses, but the structure of NCD 113 is a positive coverage list — if the indication isn't named, it isn't covered.

The BOS indication has a hard boundary. ECP for BOS outside a qualifying clinical research study is not covered. This is explicit in the policy language. Billing ECP for BOS as routine care will generate a denial, and a prior authorization — if obtained without the research study requirement attached — will not fix the problem.

Reimbursement for off-label ECP applications — including conditions like Crohn's disease, pemphigus, scleroderma, or solid organ rejection outside the cardiac allograft indication — is not authorized by this NCD. If your MAC has a local coverage determination (LCD) that addresses additional indications, that LCD governs, not national policy. Always check for an active LCD at your MAC before assuming national non-coverage is final.

---

Coverage Indications at a Glance

---

CMS Extracorporeal Photopheresis Billing Guidelines and Action Items 2026

The absence of specific CPT or HCPCS codes in NCD 113 is a real operational problem. It means your billing team cannot anchor claim submission to a code table within this policy. Here's how to respond to the March 7, 2026 modification.

Copy Action Items

If you're unsure how this NCD applies to your specific patient mix or transplant program, talk to your compliance officer before the March 7, 2026 effective date. The BOS research-only coverage restriction in particular has enough complexity that a compliance review is worth the time.

---

CPT, HCPCS, and ICD-10 Codes for Extracorporeal Photopheresis Under NCD 113

No Codes Listed in Policy Data

This policy does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. That is not a formatting omission on our part — NCD 113 as modified does not include a code table.

This makes extracorporeal photopheresis billing more complex, not less. Your claim submission depends entirely on:

• The codes your MAC accepts and has documented in a billing article or LCD
• Your charge description master (CDM) entries for ECP
• The diagnosis codes your providers document against the three covered indications

Do not attempt to infer codes from analogous procedures. Contact your MAC directly, or work with your billing consultant to identify the correct procedure code stack for your ECP claims before the March 7, 2026 effective date.

---